GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vectus Biosystems Ltd (ASX:VBS) » Definitions » Shares Outstanding (EOP)

Vectus Biosystems (ASX:VBS) Shares Outstanding (EOP) : 53.21 Mil (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Vectus Biosystems Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Vectus Biosystems's shares outstanding for the quarter that ended in Dec. 2023 was 53.21 Mil.

Vectus Biosystems's quarterly shares outstanding increased from Jun. 2023 (53.19 Mil) to Dec. 2023 (53.21 Mil). It means Vectus Biosystems issued new shares from Jun. 2023 to Dec. 2023 .

Vectus Biosystems's annual shares outstanding increased from Jun. 2022 (36.26 Mil) to Jun. 2023 (53.19 Mil). It means Vectus Biosystems issued new shares from Jun. 2022 to Jun. 2023 .


Vectus Biosystems Shares Outstanding (EOP) Historical Data

The historical data trend for Vectus Biosystems's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vectus Biosystems Shares Outstanding (EOP) Chart

Vectus Biosystems Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only 23.65 31.66 36.26 53.19 53.21

Vectus Biosystems Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.26 53.19 53.19 53.21 53.21

Competitive Comparison of Vectus Biosystems's Shares Outstanding (EOP)

For the Biotechnology subindustry, Vectus Biosystems's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vectus Biosystems's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vectus Biosystems's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Vectus Biosystems's Shares Outstanding (EOP) falls into.



Vectus Biosystems Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Vectus Biosystems  (ASX:VBS) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Vectus Biosystems Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Vectus Biosystems's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Vectus Biosystems Business Description

Traded in Other Exchanges
N/A
Address
26-34 Dunning Avenue, Unit 5, Ground Floor, Rosebery, Sydney, NSW, AUS, 2018
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company has developed and patented various novel compounds for the treatment of chronic fibrosis, including heart, kidney, liver, and lung fibrosis. Its drug candidate VB0004, is aimed at inhibiting and reversing the loss of functional tissue due to fibrosis, is in its human trials phase. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. It operates in one segment, being pharmaceutical research and development.

Vectus Biosystems Headlines

No Headlines